02197 CLOVER BIO-B
- 0.345
- -0.015-4.17%
CLOVER BIO-B News
三葉草生物-B：2023年度報告
Clover Biopharmaceuticals' RSV Vaccine Candidate Shows Promise in Early Trial
Clover Biopharmaceuticals (HKG:2197) announced positive preliminary results from the Phase 1 clinical trial of its SCB-1019 vaccine candidate for respiratory syncytial virus (RSV) in Australia, accord
Clover Bio-B (02197.HK) Announces Bivalent RSV Vaccine Candidate SCB-1019 Phase I Clinical Trial Receives Positive Preliminary Data
Gelonghui, April 8, 丨 Clover Bio-B (02197.HK) announced that in the phase I clinical trial of the bivalent RSV PreF-trimer subunit vaccine candidate SCB-1019 developed by the evaluation company based on Clover Biotech's unique Trimer-Tag (protein trimerization) vaccine technology platform, the first batch of young adults obtained positive preliminary immunogenicity and safety data. In the phase I clinical trial, the first group of young adults (ages 18-59) received SCB-1019 or saline placebo on day 0 (before vaccination) and day 28 (vaccination), respectively
Clover Bio-B (02197) granted a total of 9.463 million share options under the initial public offering after-sales share option plan
Clover Bio-B (02197) issued an announcement. On April 2, 2024, the company announced after the initial public sale...
Clover Biopharmaceuticals Trims Losses in 2023
Clover Biopharmaceuticals (HKG:2197) posted a loss attributable to the owners of 138.5 million yuan for the year ended Dec. 31, 2023, compared with a loss of 2.45 billion yuan in the previous year, ac
Clover Bio-B (02197) released annual results, spent 650 million yuan on R&D, and achieved many important milestones in R&D, production and commercialization
Clover Bio-B (02197) announced results for the year ended December 31, 2023, with revenue of 3925...
CLOVER BIO-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023 AND PROPOSED AMENDMENTS TO THE MEMORANDUM AND ARTICLES OF ASSOCIATION
Clover Bio-B (02197.HK) plans to hold a board meeting on March 26 to approve annual results
Glonghui March 14 | Clover Bio-B (02197.HK) announced that the company will hold a board meeting on March 26, 2024 (Tuesday) to consider and approve the annual results and announcements of the company and its subsidiaries for the year ended 31 December 2023, and to evaluate the payment of the final dividend.
CLOVER BIO-B: DATE OF BOARD MEETING
Hong Kong Stock Concept Tracking | The first and only in China! Nicevir monoclonal antibody was approved in China, and many companies snatched the 10 billion blue ocean (with concept stocks)
On January 2, AstraZeneca and Sanofi jointly announced that the long-acting monoclonal antibody Nirsevimab/nirsevimab (nirsevimab), which was jointly developed by the two companies, was officially approved for marketing by the China Drug Administration to prevent lower respiratory tract infections caused by respiratory syncytial virus (RSV) in newborns and infants.
Clover Biopharmaceuticals Publishes Positive Results From SCB-219M Clinical Trial
Clover Biopharmaceuticals (HKG:2197) published positive results from the phase I clinical trial on the drug SCB-219M as a treatment of cancer patients with chemotherapy-induced thrombocytopenia. The
Clover Bio-B (02197.HK) announces positive data from phase I clinical trial of SCB-219M, a targeted drug for tumor chemotherapy-related thrombocytopenia (CIT)
Gelonghui, December 29 | Clover Bio-B (02197.HK) announced that positive preliminary safety, efficacy, and pharmacokinetics data were obtained in a phase I clinical trial evaluating a new class of drugs SCB-219M. SCB-219M is an innovative bispecific Fc fusion protein-targeting drug containing a thrombocytopenic receptor agonist (TPO-RA) modeptide produced by CHO cells for thrombocytopenia (“CIT”) induced by chemotherapy in cancer patients. This phase I clinical trial is a multicenter, open, dose climbing and dose amplification study
Changes in Hong Kong stocks | Clover Bio-B (02197) rose nearly 5% to launch phase I clinical trial of RSV vaccine candidate
Clover Bio-B (02197) rose nearly 5%. As of press release, it was up 4.92% to HK$0.64, with a turnover of HK$1,464,200.
Clover Biopharmaceuticals Completes Patient Enrollment for Australia Phase 1 Trial; Shares Fall 5%
Clover Biopharmaceuticals (HKG:2197) completed patient enrollment for its phase 1 trial for its respiratory syncytial virus vaccine candidate in Australia, a Wednesday filing said. The phase 1 clinica
Clover Bio-B (02197.HK): Initiating Phase I Clinical Trials of RSV Vaccine Candidate
On December 13|Clover Bio-B (02197.HK) announced that in the phase I human clinical trial evaluating the company's respiratory syncytial virus (“RSV”) PreF - trimeric subunit vaccine candidate (SCB-1019), the first batch of subjects had completed enrollment. The vaccine candidate was developed based on the company's unique and innovative protein trimerization (Trimer-Tag) vaccine technology platform. According to disclosure, SCB-1019 is a bivalent recombinant protein RSV candidate vaccine containing two F antigens with stable pre-fusion conformations (A and B subtype RSVF proteins)
Hong Kong stocks closed (12.11) | The Hang Seng Index closed down 0.81%, the Internet, consumption, etc. were sluggish, Li Ning (02331) fell 14%, leading the decline in blue chips
The three major indices of Hong Kong stocks fluctuated and declined after opening collectively low in early trading. Among them, the Hang Seng Index once fell below the 16,000 mark in the intraday period and continued to hit a new low during the year; the decline narrowed in the afternoon.
Hong Kong Stock Concept Tracking | Institutions Entering a Period of High Incidence of Respiratory Diseases: It is recommended to focus on investment opportunities such as drug supply, testing, and vaccination (with concept stocks)
Minsheng Securities said that there is a high incidence of respiratory infectious diseases in winter, so it is recommended to pay attention to the increase in terminal demand for products such as influenza vaccines, respiratory disease drugs, and respiratory pathogen testing.
Zhitong decision reference | Observe whether the 20-day EMA can be effectively stabilized
The trend of the Hang Seng Index was relatively normal for most of the time last week, but the abnormal popularity of the Beijing Stock Exchange on Friday disrupted the overall pace of the market. The Hang Seng Index was also affected.
Hong Kong Stock Concept Tracking | Positive Influenza Test Rates Continue to Rise, Listed Pharmaceutical Companies' Demand Rises or Catalyzes Performance Growth (with Concept Stocks)
Industry insiders pointed out that the recent rise in the influenza epidemic may trigger an increase in public and market attention, thus driving an increase in demand surrounding influenza.
Changes in Hong Kong stocks | Clover Bio-B (02197) rose more than 7%, and companies with broad market space for the RSV vaccine accelerate SCB-1019 vaccine development
Clover Bio-B (02197) rose more than 7%. As of press release, it was up 7.14% to HK$0.75, with a turnover of HK$1,9181,000.
Analysis
Price Target
No Data
